Unapproved stem-cell therapies marketed to people with long COVID
New research has identified 38 direct-to-consumer businesses marketing stem-cell treatments and exosome therapies for COVID-19 infections and, especially, long COVID, despite lacking approval by US Food and Drug Administration and other regulatory body in the…








